Arrowhead Pharmaceuticals Inc. has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended September 30, 2024. The amendment, filed as Form 10-K/A, was made solely to include information required by Items 10 through 14 of Part III of Form 10-K, which was not included in the original report. This information, primarily sourced from the company's Definitive Proxy Statement filed on January 29, 2025, is current as of January 28, 2025. No other changes or updates to financial or other data were made, and the amendment does not reflect any events occurring after the dates of the original filings. The full filing can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879407-25-000013), on October 10, 2025, and is solely responsible for the information contained therein.